Cargando…
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat
Citarinostat (ACY-241) is a promising oral histone deacetylase 6 (HDAC6)-selective inhibitor currently in clinical trials for the treatment of multiple myeloma (MM) and non-small-cell lung cancer (NSCLC). However, the inevitable emergence of resistance to citarinostat may reduce its clinical effecti...
Autores principales: | Wu, Chung-Pu, Hung, Cheng-Yu, Lusvarghi, Sabrina, Chang, Yen-Fu, Hsiao, Sung-Han, Huang, Yang-Hui, Hung, Tai-Ho, Yu, Jau-Song, Ambudkar, Suresh. V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961520/ https://www.ncbi.nlm.nih.gov/pubmed/33807514 http://dx.doi.org/10.3390/ijms22052592 |
Ejemplares similares
-
The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2019) -
ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines
por: Wu, Chung-Pu, et al.
Publicado: (2023) -
Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020) -
Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023) -
Use of photoimmunoconjugates to characterize ABCB1 in cancer cells
por: Liang, Barry J., et al.
Publicado: (2021)